In this episode, Cara Wells, PhD, shares her journey from academia to entrepreneurship, detailing her experiences with fundraising, market disruption, and the challenges of navigating the startup landscape. She discusses her first venture, Embryotics, the lessons learned from its dissolution, and the ongoing legal battles stemming from her whistleblower actions. Cara also introduces her current company, Emgenisys, which focuses on innovative solutions for embryo health using machine learning. She emphasizes the importance of owning intellectual property, building a strong founding team, and the realities faced by PhD graduates in the job market.
Dr. Cara Wells is a scientist and entrepreneur with a PhD in Animal Science from Texas Tech University, specializing in reproductive physiology and assisted reproductive technologies in animals and humans. She is the founder and CEO of EmGenisys, where she leads the development of software to improve embryo evaluation and pregnancy outcomes in IVF and embryo transfer. Her earlier experience co-founding Embryotics—an effort that highlighted the challenges of commercializing university-owned IP—helped shape her more strategic and scalable approach at EmGenisys.
Music by Eggy Toast
00:00 The Biggest Learnings After Raising 1.5M03:52 How to Market a Disruptive Product 07:17 Breaking into the Global Market to get 2.5M Euro12:28 Cracking the Code on the Grant Process14:29 Going from PhD to Product Idea22:03 The Disconnect Every PhD Should Understand 24:38 Dan and Cara Rip Apart Higher Education31:46 Commercialization Challenges and Dream Team Drama39:21 How NOT to Lose Your IP and Equity44:44 The Crazy Story of The Texas Tech Lawsuit 54:16 Not Giving Up with EmGenisys56:58 The Option Pool Pro Tip for Founders01:03:36 The Value of Contractors in Startups 01:08:55 The Future of EmGenisys
